Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes

Urology. 1995 Sep;46(3):277-89. doi: 10.1016/S0090-4295(99)80208-8.
No abstract available

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Aged
  • Combined Modality Therapy
  • Cryosurgery
  • Follow-Up Studies
  • Humans
  • Insurance, Health, Reimbursement / legislation & jurisprudence*
  • Male
  • Mass Screening / economics*
  • Mass Screening / legislation & jurisprudence
  • Medicare / legislation & jurisprudence*
  • Neoplasm Staging
  • Predictive Value of Tests
  • Prostate-Specific Antigen / analysis*
  • Prostatectomy / methods
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / economics
  • Prostatic Neoplasms / therapy*
  • Radiotherapy
  • Risk Factors
  • Treatment Outcome
  • United States

Substances

  • Prostate-Specific Antigen